Journal
GENOME BIOLOGY
Volume 11, Issue 2, Pages -Publisher
BMC
DOI: 10.1186/gb-2010-11-2-r18
Keywords
-
Funding
- Belgian National Foundation for Research FNRS
- MEDIC Foundation
- European Commission
Ask authors/readers for more resources
Early gene expression studies classified breast tumors into at least three clinically relevant subtypes. Although most current gene signatures are prognostic for estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancers, few are informative for ER negative/HER2 negative and HER2 positive subtypes. Here we present Gene Expression Prognostic Index Using Subtypes (GENIUS), a fuzzy approach for prognostication that takes into account the molecular heterogeneity of breast cancer. In systematic evaluations, GENIUS significantly outperformed current gene signatures and clinical indices in the global population of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available